Skip to main content
    C

    Charles River Laboratories (CRL)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NYSE

    $335.46
    -2.51 (-0.74%)

    Market Cap: $16.19B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Charles River Laboratories (CRL) Financials: Revenue, Profit and Cash Flow

    Updated Nov 4, 2026. Financial statements from company filings, amounts in US dollars.

    Charles River Laboratories reported revenue of $4.02B for the fiscal year ended Dec 31, 2025, down 0.9% from the year before. That year, net income was -$142.16M with a net margin of -3.5%, operating cash flow was $737.65M and free cash flow was $518.49M. The quarter ended Sep 30, 2026 had revenue of $982.73M and net income of $334.44M.

    Revenue and Margins

    The operating margin was 0.6% in the fiscal year ended Dec 2025, the lowest of the 10 years shown. Over the 9 years to Dec 2025, revenue grew from $1.68B, a compound annual rate of 10.2%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$4.02B-0.9%33.0%0.6%-3.5%
    Dec 2024$4.05B-1.9%32.9%5.6%0.6%
    Dec 2023$4.13B+3.9%36.4%14.9%11.6%
    Dec 2022$3.98B+12.3%36.8%16.4%12.4%
    Dec 2021$3.54B+21.1%37.7%16.7%11.3%
    Dec 2020$2.92B+11.5%36.7%14.8%12.5%
    Dec 2019$2.62B+15.7%36.6%13.4%9.7%
    Dec 2018$2.27B+22.0%37.1%14.6%10.1%
    Dec 2017$1.86B+10.5%37.7%15.5%6.8%
    Dec 2016$1.68BN/A38.3%14.1%9.3%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the company posted a net loss after a profit the year before. In the quarter ended Sep 2026, net income rose 501.9% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$4.02B$4.05B$4.13B$3.98B$3.54B$2.92B$2.62B$2.27B$1.86B$1.68B
    Cost of revenue$2.69B$2.72B$2.63B$2.51B$2.21B$1.85B$1.66B$1.43B$1.16B$1.04B
    Gross profit$1.32B$1.33B$1.50B$1.46B$1.33B$1.07B$958.31M$840.07M$700.92M$643.96M
    Operating income$25.16M$227.35M$617.26M$650.98M$589.86M$432.73M$351.15M$331.38M$288.28M$237.55M
    Net income-$142.16M$25.29M$480.37M$492.61M$398.84M$365.31M$254.06M$228.72M$125.45M$156.37M
    EBITDA$405.90M$572.57M$1.03B$985.37M$819.51M$767.64M$561.54M$506.42M$457.20M$375.97M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$982.73M$1.00B$995.83M$994.23M$1.00B$1.03B$984.17M$1.00B$1.01B$1.03B$1.01B$1.01B
    Gross profit$357.87M$363.37M$294.66M$309.68M$338.79M$357.07M$317.73M$284.24M$349.02M$353.71M$344.84M$364.08M
    Operating income$202.64M$119.89M$119.90M-$283.44M$133.80M$100.13M$74.67M-$167.69M$117.41M$151.65M$125.98M$132.92M
    Net income$334.44M-$760.00K-$14.80M-$276.29M$55.56M$52.69M$25.88M-$213.75M$70.30M$94.26M$74.48M$188.95M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $2.20B exceeded cash and equivalents by $1.98B.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$7.14B$7.53B$8.20B$7.60B$7.02B$5.49B$4.69B$3.86B$2.93B$2.71B
    Current assets$1.45B$1.40B$1.61B$1.44B$1.27B$1.20B$1.02B$897.84M$826.63M$656.83M
    Cash and equivalents$213.77M$194.61M$276.77M$233.91M$241.21M$228.42M$238.01M$195.44M$163.79M$117.63M
    Total liabilities$3.92B$4.02B$4.54B$4.58B$4.43B$3.35B$3.03B$2.52B$1.87B$1.86B
    Short-term debt$61.06M$114.02M$441.12M$50.20M$36.06M$50.21M$38.55M$31.42M$31.00M$27.31M
    Long-term debt$2.14B$2.24B$2.65B$2.71B$2.66B$1.93B$1.85B$1.64B$1.11B$1.21B
    Shareholder equity$3.16B$3.46B$3.60B$2.98B$2.53B$2.11B$1.63B$1.32B$1.05B$836.77M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$7.45B$7.53B$7.73B$7.14B$7.51B$7.56B$7.58B$7.53B$8.00B$7.95B$8.15B$8.20B
    Total liabilities$4.18B$4.64B$4.74B$3.92B$4.06B$4.16B$4.34B$4.02B$4.18B$4.18B$4.45B$4.54B
    Cash and equivalents$200.38M$192.03M$191.83M$213.77M$207.10M$182.82M$229.36M$194.61M$210.17M$179.21M$327.04M$276.77M
    Shareholder equity$3.23B$2.84B$2.94B$3.16B$3.41B$3.35B$3.19B$3.46B$3.78B$3.72B$3.64B$3.60B
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 70.3% of operating cash flow. Share repurchases came to 69.6% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$737.65M$734.58M$683.90M$619.64M$760.80M$546.58M$480.94M$441.14M$318.07M$316.90M
    Capital expenditures$219.15M$232.97M$318.53M$324.73M$228.77M$166.56M$140.51M$140.05M$82.43M$55.29M
    Free cash flow$518.49M$501.61M$365.37M$294.91M$532.03M$380.01M$340.42M$301.09M$235.64M$261.61M
    Dividends paidN/AN/A$25.60MN/A$45.65M$46.59M$34.55MN/A$0$0
    Share repurchases$360.67M$119.17M$24.16M$38.65M$40.71M$23.98M$18.09M$13.85M$106.91M$12.27M
    Investing cash flow-$209.32M-$245.09M-$563.15M-$607.92M-$1.44B-$601.54M-$681.50M-$955.00M-$72.59M-$692.67M
    Financing cash flow-$536.73M-$550.93M-$85.52M-$42.40M$672.60M$47.25M$231.94M$558.06M-$208.48M$380.76M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$254.09M$179.72M$41.08M$147.52M$213.83M$204.60M$171.70M$159.36M$251.79M$193.53M$129.89M$220.94M
    Capital expenditures$46.81M$31.11M$55.91M$88.95M$35.58M$35.30M$59.32M$75.62M$38.72M$39.49M$79.14M$78.32M
    Free cash flow$207.28M$148.62M-$14.83M$58.57M$178.25M$169.31M$112.37M$83.75M$213.07M$154.05M$50.74M$142.62M
    Last 12 quarters

    Frequently Asked Questions About CRL

    What is Charles River Laboratories' annual revenue?

    Charles River Laboratories reported revenue of $4.02B for the fiscal year ended Dec 31, 2025.

    How fast is Charles River Laboratories' revenue growing?

    Revenue was down 0.9% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 0.3%.

    Is Charles River Laboratories profitable?

    No. Charles River Laboratories reported net income of -$142.16M for the fiscal year ended Dec 31, 2025, with a net margin of -3.5%.

    How much free cash flow does CRL generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $737.65M minus capital expenditures of $219.15M produced free cash flow of $518.49M.

    How much debt does Charles River Laboratories have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $2.14B, short-term debt of $61.06M and cash and equivalents of $213.77M.